Products
Data
Feature
Plans
Request Demo
Sign Up for Free
Blog
Valuable Targets
Advanced Tech.
Recent blog posts
Latest Hotspot
8 min read
MARCO Biologics Sequence Review Report 2026: Macrophage receptor MARCO Similarity and Patent-Risk Signals
17 September 2026
A Biology Modality MCP review of MARCO sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
Latest Hotspot
8 min read
MAGEE1 Biologics Sequence Review Report 2026: Melanoma-associated antigen E1 Similarity and Patent-Risk Signals
17 September 2026
A Biology Modality MCP review of MAGEE1 sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
Latest Hotspot
8 min read
MAGED4 Biologics Sequence Review Report 2026: Melanoma-associated antigen D4 Similarity and Patent-Risk Signals
17 September 2026
A Biology Modality MCP review of MAGED4 sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
Latest Hotspot
8 min read
MAGED2 Biologics Sequence Review Report 2026: Melanoma-associated antigen D2 Similarity and Patent-Risk Signals
17 September 2026
A Biology Modality MCP review of MAGED2 sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
Latest Hotspot
8 min read
MAGED1 Biologics Sequence Review Report 2026: Melanoma-associated antigen D1 Similarity and Patent-Risk Signals
17 September 2026
A Biology Modality MCP review of MAGED1 sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
Latest Hotspot
8 min read
MAGEC3 Biologics Sequence Review Report 2026: Melanoma-associated antigen C3 Similarity and Patent-Risk Signals
17 September 2026
A Biology Modality MCP review of MAGEC3 sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
Latest Hotspot
8 min read
MAGEC2 Biologics Sequence Review Report 2026: Melanoma-associated antigen C2 Similarity and Patent-Risk Signals
17 September 2026
A Biology Modality MCP review of MAGEC2 sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
Latest Hotspot
8 min read
MAGEB6 Biologics Sequence Review Report 2026: Melanoma-associated antigen B6 Similarity and Patent-Risk Signals
17 September 2026
A Biology Modality MCP review of MAGEB6 sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
Latest Hotspot
8 min read
MAGEB4 Biologics Sequence Review Report 2026: Melanoma-associated antigen B4 Similarity and Patent-Risk Signals
17 September 2026
A Biology Modality MCP review of MAGEB4 sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
Latest Hotspot
8 min read
MAGEB2 Biologics Sequence Review Report 2026: Melanoma-associated antigen B2 Similarity and Patent-Risk Signals
17 September 2026
A Biology Modality MCP review of MAGEB2 sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
Latest Hotspot
8 min read
MAGEB18 Biologics Sequence Review Report 2026: Melanoma-associated antigen B18 Similarity and Patent-Risk Signals
17 September 2026
A Biology Modality MCP review of MAGEB18 sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
Latest Hotspot
8 min read
MAGEA8 Biologics Sequence Review Report 2026: Melanoma-associated antigen 8 Similarity and Patent-Risk Signals
17 September 2026
A Biology Modality MCP review of MAGEA8 sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
<
1
<<
4
5
6
7
8
>>
1245
>